June 3, 2022 Columns by Ed Tobias A Road Trip From Florida to Maryland With No Bladder Incontinence After two days ā 16 hours of it spent on the road ā and 1,104 miles, I hadn’t had a single accident. My bladder control meds must’ve worked. The semiannual trip my wife and I take between Florida’s southwest coast and the suburbs of Washington, D.C. is never…
March 24, 2022 News by Marisa Wexler, MS STAT5 Protein Complex Implicated in MS Autoimmunity in Mice A four-protein complex, or tetramer, of the protein STAT5 is involved in the development of multiple sclerosis (MS)-like autoimmune disease in mice, a new study shows. The findings point to this protein complex and its signaling pathway as a potential treatment in MS and other autoimmune conditions, scientists noted.
January 3, 2022 News by Marisa Wexler, MS Top 10 Multiple Sclerosis Stories of 2021 Multiple Sclerosis News TodayĀ brought you daily coverage of the latest scientific research, advances in treatment, and clinical trials related to multiple sclerosis (MS) throughout 2021. We look forward to continuing to be a resource for the MS community in 2022. Here are the Top 10 most-read articles of…
August 9, 2021 News by Marisa Wexler, MS US Survey Finds High Rates of Dissatisfaction With Quality of Life, But Satisfaction With Healthcare More than one-third of people with multiple sclerosis (MS) who responded to an online U.S.-based survey are dissatisfied with their quality of life, and more than one in four MS patients are pessimistic about their future, according to the results of the survey, conducted by Multiple Sclerosis News…
July 26, 2021 News by Marisa Wexler, MS Gilenya Started Earlier in RRMS Disease Course in Recent Years People with relapsing-remitting multiple sclerosis (RRMS) have switched to treatment with Gilenya (fingolimod) at an earlier stage in their disease in recent years, compared to individuals who switched to the treatment around the time it became available, a new study indicates. The findings suggest “an increased experience in…
April 28, 2021 News by Marisa Wexler, MS #AANAM ā Research Focuses on Measuring Therapeutic Lag Editorās note: TheĀ Multiple Sclerosis News TodayĀ team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, held April 17ā22. GoĀ hereĀ to read the latest stories from the conference. A novel method to calculate how long it takes therapies for multiple sclerosis (MS) to become fully effective…
March 3, 2021 News by Marisa Wexler, MS #ACTRIMS2021 – Research Finds Race- and Ethnicity-based Differences in MS Therapies Editorās note: TheĀ Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25ā27. GoĀ hereĀ to see the latest stories from the conference. Clinical characteristics of multiple sclerosis (MS) patients, including their response to therapies, vary based on race and ethnicity,…
January 7, 2021 News by Patricia Inacio, PhD MS Patient Donates $700,000 to Ochsner MS Work Desi Harrison, a multiple sclerosis (MS) patient and president of the nonprofit MS Warriors for a Cause, has donated $700,000 to support the Ochsner Neuroscience Institute. The funds will help support research and care at theĀ Ochsner Multiple Sclerosis Center to ensure that patients ā like Harrison, who…
November 21, 2019 News by Marisa Wexler, MS WCN 2019 Discussions Point to Failures of Regulators to Make MS Therapies Available There is a sizable gap between advancements in treatment for multiple sclerosis (MS)Ā and their regulatory approval, which is a circumstance that necessitates increased Ā advocacy on a global scale. This concern was a major topic of conversation recently at theĀ XXIV World Congress of NeurologyĀ (WCN 2019)…
November 20, 2019 News by Marta Figueiredo, PhD Pregnancy Does Not Change Long-term Course of MS, New Data Suggest Pregnancy does not lead to long-term changes in the disease course ofĀ multiple sclerosisĀ (MS), new research suggests. This work, which emphasizes the importance of careful data analysis, supports studies disputing previous beliefs that pregnancy worsened or lessened the long-term disease course of MS. The findings were presented by Mar Tintore,…
November 14, 2019 Columns by Tamara Sellman Need to Know: 21st-century Medicine Models Editor’s note: “Need to Knowā is a series inspired by common forum questions and comments from readers. Have a comment or question about MS? Visit our forum. This week’s question is inspired by the forum topicĀ “Do We Need a Personalized Approach to Treating MS?” from May 23,…
September 27, 2019 News by Mary Chapman Michiganās Memorial Healthcare First in US to Test NfL in MS Patients Memorial Healthcare Institute for Neurosciences and Multiple SclerosisĀ announced it will become the first U.S. hospital to test a nerve cell-derived component known as neurofilament light chain (NfL) in multiple sclerosis (MS) patients. Led by the Owosso, Michigan, hospitalās chief of neurology and MS director, Rany Aburashed, DO,…
September 11, 2019 News by Ana Pena PhD #ECTRIMS2019 ā MS Patients Should Be Informed about Pregnancy Risks and Family Planning, Experts Say While pregnancy does not appear to affect the disease course of multiple sclerosis (MS), questions remain about the best time to stop or resume treatment before conception and after delivery, the safety of new medications, and the importance of family planning. Pregnancy was the “hot topic” discussion today…
June 13, 2019 News by Alice MelĆ£o, MSc DELIVER-MS Trial Recruiting RRMS Patients to Help Improve Treatment Decision-making A clinical trial based at the Cleveland Clinic and the University of Nottingham, U.K., is recruiting patients with relapsing-remitting multiple sclerosis (RRMS) to compare two treatment strategies, the National Multiple Sclerosis Society announced. The Phase 4 study, called DELIVER-MS (NCT03535298), intends to enroll about 800…
June 5, 2019 News by Mary Chapman 12-part Video Series, ‘Understanding Multiple Sclerosis,’ Available Online In partnership with @Point of Care, the Multiple Sclerosis Association of America (MSAA) is offering a comprehensive educational video series about multiple sclerosis (MS). The concise, 12-part series ā titled āUnderstanding Multiple Sclerosisā ā Ā features neurologist and MS expert Michelle T. Fabian, MD, and covers…
May 28, 2019 News by Patricia Inacio, PhD Experts Gather for Consortium of Multiple Sclerosis Centers Annual Meeting The latest research in multiple sclerosis (MS), along with the most recent advancements in treatment strategies and comprehensive care, will be presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting, which beings today. Running through June 1 at the Washington State Convention Center in Seattle, the…
April 16, 2019 Columns by Ed Tobias Cancer Medication Shows Promise in Treating Dangerous Brain Infection PML, Small-scale Study Finds Progressive multifocal leukoencephalopathy, more commonly referred to as PML, is a brain infection that’s frequently fatal.Ā PML is particularly dangerous to people with MS, which is why I’m interested in a report about a medication that’s showing promise as a PML treatment. The concern for people with MS is…
April 2, 2019 News by Joana Carvalho, PhD NeurologyLive Launches Series of Educational Videos About MS NeurologyLiveĀ has launched a series of educational videosĀ intended to provide an overview of the diagnositic methods and treatment options available toĀ multiple sclerosis (MS) patients. The video series, “Advances in the Diagnosis and Management of Multiple Sclerosis,” also will include future perspectives on upcoming MS therapies,…
January 23, 2019 News by Jonathan Grinstein Novartis, Oxfordās Big Data Institute Team to Better Understand, Treat Complex Diseases NovartisĀ and the University of Oxfordās Big Data Institute (BDI) have established an alliance to advance the use of medical data for spotting disease patterns and assessing patients’ responses to treatment. The initiative seeks to enable more informed clinical decision-making and improve the development of treatments for complex diseases.
January 4, 2019 Columns by Ed Tobias MS Treatment Decisions Can Cause a ‘Gambler’s Dilemma’ One of the toughest decisions facing someone with MS is whether to begin treatment with a disease-modifying therapy (DMT). Equally tough, I think, is deciding which DMT road to travel ā because there are three roads that can be followed. One path starts you on a simple, first-level medication. These…
February 2, 2018 Columns by Jamie Hughes Rest on the Water: A Flirtation with Flotation to Find Silence Iām currently working on an essay about the power of silence. And, in the process of planning this thing, I realized I donāt do so well with it ā especially at night. So, to work my way through this topic, I began looking for ways to experience true silence.
September 28, 2017 Columns by Laura Kolaczkowski A Look Inside MS Marketplace Projections Do you ever stop and ponder the value of MS drugs? Iām not talking about if they work and the ways they improve our lives. Iām thinking of the COST of them and what their pricing means to investors. I get several market analysis reports on the pharmaceutical industry,…
September 15, 2017 News by Alice MelĆ£o, MSc Five Research Projects Totaling $38 Million to Compare Effectiveness of MS Treatment Strategies The Patient-Centered Outcomes Research InstituteĀ has awarded $38 million in grants for five projects that compare the effectiveness of different multiple sclerosis treatment strategies. A key aim of the research is to improve knowledge about the therapiesĀ to help doctors and patients choose the healthcare option that best meets patients’ needs.Ā The…
June 23, 2017 News by Patricia Silva, PhD Nurse Advocates for Shared Decision-Making to Treat MS Shared decision-making between patients and their doctors and healthcare providers was considered a critical step in the process of treatingĀ multiple sclerosis (MS), according toĀ an article published in the journal Practical Neurology. The article āShared Decision-making in Multiple Sclerosis Managementā was written by Amy Perrin Ross, a board-certified…
May 18, 2017 News by Patricia Silva, PhD Ocrevus Market Entry Already Changing Dynamics in MS Treatment Choices, Spherix Analysis Suggests Multiple sclerosis (MS) patients are largely moving away from injectable drugs and towards oral treatments when they switch from first to second-line MS therapies. ButĀ that might change with theĀ introduction of Ocrevus (ocrelizumab), whichĀ has becomeĀ the drug of choice for manyĀ neurologists advising patients on drug switches. The real-world analysis by…
April 27, 2017 Columns by Tamara Sellman Latest Research Bolsters My Confidence in Using Tecfidera Many life-affecting decisions are made at the time of an MS diagnosis. Top of the list? The moment you decideĀ your course of treatment. In my case, the decision wasĀ entirely up to me. This isn’t typical, I’ve discovered. Many people with MS aren’t…
April 12, 2017 Columns by Laura Kolaczkowski RMS Patient Using Ocrevus in Trial: ‘I Feel Great’ Pamela Arterbridge is one of 70 people at Ohio State Universityās Multiple Sclerosis Center taking part in the open-label part of aĀ clinical trial for ocrelizumab, nowĀ best known asĀ Ocrevus.Ā She is a patient of Dr. Michael Racke, who is a pioneer in the field of B-cell treatmentsĀ for MS,…
January 24, 2017 Columns by Ed Tobias Pills, Shots or Infusions for Your MS? Oral multiple sclerosis meds appear, more and more, to be the first choice of patients who are just beginning to receive an MS treatment. A recent report by the independent marketing research firmĀ Spherix Global Insights shows thatĀ oral disease-modifying therapies captured a significantly higher…
January 19, 2017 Columns by Laura Kolaczkowski Resolving Insurance Problems Demands Patience and Endurance After my recent insurance experience, which I share here, I never again will wonder why some people give up on claiming their medical benefits. I have received Botox treatment for spasticity of my quad and hamstring muscles. This is an FDA-approved use, but to get this treatment there has…
January 10, 2017 Columns by Ed Tobias Lemtrada for My MS: First Month Report It’s been a month since I completed my first round of Lemtrada infusions, so it’s time to bring everyone up to date on how things are going. I was told to expect a roller coaster of side effects. I’m pleased to say that, at least so far, it’s…